<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799265</url>
  </required_header>
  <id_info>
    <org_study_id>800383</org_study_id>
    <nct_id>NCT01799265</nct_id>
  </id_info>
  <brief_title>Transcend Auto Clinical Evaluation</brief_title>
  <official_title>Transcend Auto Clinical Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Somnetics International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Somnetics International, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Transcend Auto is as effective in
      treating obstructive sleep apnea as another device that is already on the market.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, crossover trial.  Patients will be randomized 1:1 to
      undergo two full night sleep studies with the Transcend Auto and a commercially available
      device.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean apnea hypopnea index during treatment</measure>
    <time_frame>first and second night sleep study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apnea hypopnea index will be measured during treatment with each of the devices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>unanticipated adverse device effects</measure>
    <time_frame>first and second night sleep study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be monitored for unanticipated adverse device effects during each sleep study. Patients will not be followed after the second sleep study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apnea index and hypopnea index during treatment</measure>
    <time_frame>first and second night sleep study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Transcend followed by REMstar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive treatment with Transcend during the first night sleep study, followed by treatment with the REMstar on the second night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REMstar followed by Transcend</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will receive treatment with REMstar during the first night sleep study followed by treatment with Transcend on the second night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Somnetics Transcend Auto</intervention_name>
    <arm_group_label>Transcend followed by REMstar</arm_group_label>
    <arm_group_label>REMstar followed by Transcend</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respironics REMstar Auto with C-Flex</intervention_name>
    <arm_group_label>Transcend followed by REMstar</arm_group_label>
    <arm_group_label>REMstar followed by Transcend</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult 18 years of age or older

          -  Diagnosis of obstructive sleep apnea

          -  Presently using CPAP or APAP therapy

        Exclusion Criteria:

          -  Central or mixed apnea
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Powell, PhD RPSGT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleep Therapy and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwind Lung Specialists and Sleep Center</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitney Sleep Center</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 13, 2013</lastchanged_date>
  <firstreceived_date>February 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>OSA</keyword>
  <keyword>AutoPAP</keyword>
  <keyword>PAP</keyword>
  <keyword>sleep disordered breathing</keyword>
  <keyword>CPAP</keyword>
  <keyword>Apnea hypopnea index</keyword>
  <keyword>AHI</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
